Emerging Real-World Evidence Suggests Differential Outcomes Between Abiraterone and Darolutamide in Hormone-Sensitive Prostate Cancer

Agents such as abiraterone and darolutamide have demonstrated significant survival benefits in randomized clinical trials, yet direct comparative evidence between these therapies, particularly in the pre-chemotherapy setting, remains notably absent.

A recent retrospective cohort analysis leveraging the TriNetX database attempts to address this gap by comparing real-world outcomes in patients treated with ADT plus either abiraterone or darolutamide, excluding prior exposure to docetaxel. After propensity score matching, 363 patients were included in each treatment arm, yielding a balanced comparison across measured baseline characteristics.

Note: this analysis should be viewed as hypothesis-generating rather than practice-defining. It raises the possibility that darolutamide may offer superior outcomes in certain real-world patient populations, but definitive conclusions require prospective, randomized comparisons.

The findings are impressive. Patients receiving abiraterone exhibited a significantly higher rate of progression to hormone-resistant disease compared with those treated with darolutamide (23.8% vs 9.1%, odds ratio 3.1, 95% CI 1.9–5.0). Furthermore, overall survival was inferior in the abiraterone cohort. Median overall survival reached 60 months in this group, whereas it was not reached in the darolutamide cohort during the study period. Kaplan–Meier analysis confirmed a statistically significant survival disadvantage associated with abiraterone (hazard ratio 1.65, 95% CI 1.14–2.37; log-rank p = 0.006). Consistently, all-cause mortality was higher among patients treated with abiraterone (OR 3.4, 95% CI 2.3–5.1).

At face value, these results suggest a clinically meaningful divergence in outcomes between two widely used ARPIs. Such findings are particularly compelling given the absence of randomized head-to-head trials and the current reliance on cross-trial comparisons to guide therapeutic decision-making.

However, the interpretation of these results warrants caution. As with all retrospective analyses, the potential for residual confounding remains substantial, even after propensity score matching. Critical prognostic variables in prostate cancer—such as disease volume, Gleason score, PSA burden, and performance status—are often incompletely captured in real-world databases. Their imbalance between cohorts could materially influence outcomes.

Source.